Steve Pipe discusses Phase 3 HOPE-B Gene Therapy Trial
First Data From the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults With Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing
Earn CME/CE credit by clicking the link below
https://bit.ly/36XFYzn